Paralel Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Paralel Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.34M	Buy	+40,919	New	+$2.24M	0.09%	75

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Paralel Advisors's BMRN Position: Q2 2026 in Review

Paralel Advisors opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2026: 40,919 shares worth $2.34M. The stake represents 0.09% of the portfolio and ranks #75 among its holdings.

561 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Paralel Advisors held 40,919 shares of BioMarin Pharmaceuticals worth $2.34M as of Q2 2026.
BioMarin Pharmaceuticals was a new Paralel Advisors position in Q2 2026.
BioMarin Pharmaceuticals made up 0.09% of Paralel Advisors's portfolio in Q2 2026, its #75 holding.
561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Paralel Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.